talacotuzumab + decitabine

Talacotuzumab + decitabine is an investigational drug combination consisting of talacotuzumab, a humanized monoclonal antibody targeting CD123, and decitabine, a hypomethylating small molecule agent. This combination was developed for the treatment of acute myeloid leukemia (AML) in elderly patients ineligible for intensive chemotherapy. Talacotuzumab binds CD123 on leukemic cells (including leukemic stem cells), leading to cell death through antibody-dependent mechanisms. Decitabine inhibits DNA methyltransferase, leading to hypomethylation of DNA and reactivation of silenced genes, exerting antineoplastic effects. In clinical studies, the combination showed no significant improvement over decitabine alone and was associated with increased toxicity, leading to early discontinuation of talacotuzumab development in this setting[1][2][3][4][5].

Other names

anti-CD123 antibody + decitabinetalacotuzumab plus decitabinetalacotuzumab and decitabine